- Policy
- The NIID-Moderna discusses the cooperation plan for R&D
- by Kim, Jung-Ju Mar 31, 2021 06:06am
- The quarantine authorities are holding a video conference with Moderna, a COVID-19 vaccine company, to discuss cooperation measures such as R&D. It plans to continue development cooperation not only with related companies but also with US research institutes. KWON Jun-wook, Vice Head of Central Disease Control Headquarters explained thi
- Policy
- Is Forxiga generic same as solvate-modified drug?
- by Lee, Tak-Sun Mar 30, 2021 06:06am
- Pharmaceutical companies developing generics of an antidiabetic Forxiga are concerned that the products would get struck by receive sales ban due to preferential sales rights. The related criteria are not clarified enough for companies to predict the result. According to the pharmaceutical industry sources on Mar. 29, the companies are h
- Policy
- Doctor's note not needed for requesting vaccination leave
- by Kim, Jung-Ju Mar 30, 2021 06:06am
- From now on, ‘vaccination leave’ on request would be able for those receiving vaccination against COVID-19, even without a doctor’s not. COVID-19 Central Disaster and Safety Countermeasures Headquarters (CDSCH) discussed promoting the COVID-19 vaccination leave for adverse reaction as reported by the Ministry of Health and Welfare (MO
- Policy
- Lot release for Pfizer's COVID-19 vaccine was completed
- by Lee, Tak-Sun Mar 30, 2021 06:05am
- The MFDS announced that it has released a national lot of 250,000 people (500,000 batches) of Comirnaty that Pfizer Korea has applied for on the 28th (Sun). The national lot release is a system that the state confirms once more the quality of the vaccine is assessed comprehensively by evaluating the results of the 'validation test' for ea
- Policy
- From drug approval to follow-up management
- by Lee, Hye-Kyung Mar 29, 2021 04:20pm
- The NHIS established drug price management from January 1 of this year, and began step-by-step management for stable supply of drugs and drug cost management. Along with the establishment of the Drug Price Management Office, the TF of the Drug Management Department was established, and an improvement plan to apply various research services c
- Policy
- 68% of the people said they plan to get vaccinated
- by Kim, Jung-Ju Mar 29, 2021 06:38am
- As vaccinations are being carried out in stages due to COVID-19 outbreak, 8 out of 10 people agree with the government to strengthen quarantine. In addition, 68% of the respondents answered that they will receive vaccinations in the future, indicating that they are aware of the importance of the vaccine. COVID-19 Central Disaster Management H
- Policy
- 6 new drugs newly listed or expanded coverage in 2021 so far
- by Kim, Jung-Ju Mar 29, 2021 05:58am
- According to the next month’s update for the pharmaceutical reimbursement list, total five items would be newly listed and improve patient access. And one already-listed drug gets to expand coverage. It is a result of enhancing the coverage based on social importance and patient needs. The South Korean government projected total 60,196 pati
- Policy
- KRW 2.85 tln for KDCA COVID-19 vaccine supplementary budget
- by Kim, Jung-Ju Mar 29, 2021 05:58am
- The Korea Disease Control and Prevention Agency (KDCA) has secured an additional budget of 2.35 trillion won for procuring COVID-19 vaccines from overseas. This reflects additional 2.30 trillion won from this year. On Mar. 25, KDCA announced that this increase was reflected as the first supplementary budget in the year 2021. The total cost of
- Company
- Controversy over 7-day packaging Rx drugs
- by Nho, Byung Chul Mar 29, 2021 05:58am
- Due to the packaging unit different from the domestic prescription style, drug prescription and storage difficulties for pharmacists and patients in countries are increasing and improvement is required. According to the pharmacy, it is difficult to dispensing some high-frequency, long-term prescription drugs because the packaging unit is s
- Company
- Boehringer is interested in open innovation with Yuhan
- by Mar 29, 2021 05:58am
- Boehringer Ingelheim emphasized the importance of open innovation and announced that it has a long-term partnership with Yuhan. It also mentioned the possibility of further open innovation for R&D materials in Korea. In addition, they expressed their will to do their best in the development of COVID-19 treatment and anticancer drugs targeting
